- Home
- » Tags
- » Lebrikizumab
Top View
- (INN) for Biological and Biotechnological Substances
- Cinqaero, INN-Reslizumab
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- Efficacy and Safety of Lebrikizumab
- WO 2019/028191 Al 07 February 2019 (07.02.2019) W !P O PCT
- Lebrikizumab - Drugbank
- 7.7 Clinical Asthma
- Biologics in Pediatric Psoriasis and Atopic Dermatitis: Revolutionizing the Treatment Landscape
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Aaai-Aid1026.Pdf
- Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab As Inhibition of Binding to IL-13Rα1 and IL-13Rα2
- Financial and Non-Financial Highlights Chugai Pharmaceutical Co., Ltd
- The Way Forward for the Refractory Asthmatic
- And Biomarker-Based Algorithm for Management of Acute Gvhd
- Emerging Therapeutic Options for the Treatment of Patients with Symptomatic Asthma R
- Roche Reviewing Next Steps for Lebrikizumab After Mixed Phase III Data
- Monoclonal Antibodies in Asthma
- Atopic Dermatitis: Novel Therapeutic Targets and Pathways1 Full Abbreviations, Accreditation, and Disclosure Information Available at Peerview.Com/KCX40
- Biological Therapy in Severe Asthma: a Gem Or a Jam Hesham Raafat
- IMMUNOLOGY Brad Frankum, Monique Wei Meng Lee and Jessie a Lee
- Treatment of Atopic Dermatitis: What’S New?
- Supplementary Information
- Phase 2 Trial to Assess Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis
- CV Blauvelt 1219
- Study Protocol
- Clinical Study Protocol Distribution of Eosinophils in Asthma After
- COVID‐19 and Immunological Regulations
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Lebrikizumab, a High Affinity IL-13
- Previously Reported Placebo-Response-Associated Variants Do Not Predict Patient Outcomes in Inflammatory Disease Phase III Trial
- Roche's Lebrikizumab Phase Iib Data Show Reduction of Asthma Attack Rates and Improvement of Lung Function in Adult Patients W
- Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names
- Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
- Prescribing Outlook 2014 - Development Delayed
- Therapies for Allergic Inflammation: Refining Strategies to Induce Tolerance
- Roche to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual
- Type 2 Inflammation in Atopic Dermatitis and Beyond: Shared Pathophysiology and Clinical Management
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- Immunomodulatory Treatment for the Intractable Paediatric Epilepsies Luis E
- Corporate Presentation Template
- A Mathematical Model to Identify Optimal Combinations of Drug
- (INN) for Biological and Biotechnological Substances
- Regulation of Eosinophilia in Asthma—New Therapeutic Approaches for Asthma Treatment
- Assessment of the Evolution of Cancer Treatment Therapies
- CV Blauvelt March 2021
- The Best of JAAD
- Cytokines in Graft-Versus-Host Disease Andrea S
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- News Releases
- Monoclonal Antibodies in Type 2 Asthma: a Systematic Review and Network Meta- Analysis Ahmed Edris1, Silke De Feyter1,2, Tania Maes2, Guy Joos2 and Lies Lahousse1*
- Dexamethasone to Reduce Stem Cell Accumulation in the Spleen
- New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration
- WO 2015/105926 Al 16 July 2015 (16.07.2015) P O PCT
- Hypersensitivity Reactions to Biologics (Part I)